Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
The trial was terminated prematurely on Oct 15, 2013 due to a business decision. The decision to terminate the trial was not based on any clinical safety or efficacy concerns.
Age
21–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and/or female subjects between the ages of 21 to 70 who have a clinical diagnosis of either discoid cutaneous lupus erythematosus or subacute cutaneous lupus erythematosus with or without systemic lupus erythematosus prior to screening that has been confirmed by evaluation of skin biopsy sample.
Active disease at both screening and baseline (Day 1) defined by a CLASI score of greater than or equal to 10.
Intolerance to antimalarial therapy or more than 3 months of antimalarial therapy with disease activity.
You may not be if
Use of greater than or equal to 20 mg or prednisone (or equivalent) within 3 months of Day 1.
Signs or symptoms or relevant history of a viral, bacterial, fungal, and parasitic infection, or recent history of repeated infections
Subjects with evidence of past or active tuberculosis
Pregnant, planning to get pregnant, and/or lactating females or males planning to father a child within time period of the study or subsequent exclusionary period.
